Latest News
Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients with SMA
Cytokinetics, Inc. today announced that the second cohort of the Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA), is open to enrollment. This clinical trial […]
Read More ›Cure SMA Coverage and Payment Policy Project Continues to Move Forward
The Cure SMA Coverage and Payment Policy Project has two distinct but complementary tracks: Outreach on behalf of our community. We’re working with public and private insurers, regulators, and other […]
Read More ›Genentech Roche Releases Community Letter with Clinical Trial Updates
Genentech Roche provided the following community statement with clinical trial updates for SUNFISH (Type 2/3), FIREFISH (Type 1) and JEWELFISH. Dear SMA community, At Genentech (A Member of the Roche […]
Read More ›Cure SMA Releases Schedule for the 2017 Annual SMA Conference
Cure SMA has released the schedule for the 2017 Annual SMA Conference, to be held at Walt Disney World in Orlando, FL, June 29 – July 2. The schedule includes […]
Read More ›Cure SMA Awards $140,000 Grant to Joceyln C̫t̩, PhD, University of Ottawa
Cure SMA has awarded a $140,000 research grant to Joceyln Côté, PhD, at The University of Ottawa, for his project, “Investigating the mechanism by which SMN regulates translation: identification of […]
Read More ›American College of Obstetricians and Gynecologists Recommends Expanded SMA Carrier Screening
The American College of Obstetricians and Gynecologists has released updated guidance on carrier testing for genetic conditions. The updated guidance includes, for the first time, a recommendation that all women […]
Read More ›